相似文献
1
PharmVar GeneFocus: CYP3A5.
Clin Pharmacol Ther. 2022 Dec;112(6):1159-1171. doi: 10.1002/cpt.2563. Epub 2022 Mar 29.
2
PharmVar GeneFocus: CYP2B6.
Clin Pharmacol Ther. 2021 Jul;110(1):82-97. doi: 10.1002/cpt.2166. Epub 2021 Mar 11.
3
PharmVar GeneFocus: CYP4F2.
Clin Pharmacol Ther. 2024 Oct;116(4):963-975. doi: 10.1002/cpt.3405. Epub 2024 Aug 13.
4
PharmVar GeneFocus: CYP2D6.
Clin Pharmacol Ther. 2020 Jan;107(1):154-170. doi: 10.1002/cpt.1643. Epub 2019 Dec 9.
5
PharmVar GeneFocus: CYP2C19.
Clin Pharmacol Ther. 2021 Feb;109(2):352-366. doi: 10.1002/cpt.1973. Epub 2020 Jul 22.
6
PharmVar GeneFocus: CYP2C9.
Clin Pharmacol Ther. 2021 Sep;110(3):662-676. doi: 10.1002/cpt.2333. Epub 2021 Jul 12.
7
PharmVar GeneFocus: SLCO1B1.
Clin Pharmacol Ther. 2023 Apr;113(4):782-793. doi: 10.1002/cpt.2705. Epub 2022 Jul 27.
8
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.
Clin Pharmacol Ther. 2015 Jul;98(1):19-24. doi: 10.1002/cpt.113. Epub 2015 Jun 3.
9
PharmVar GeneFocus: CYP2A6.
Clin Pharmacol Ther. 2024 Oct;116(4):948-962. doi: 10.1002/cpt.3387. Epub 2024 Jul 25.
10
The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.
Clin Transplant. 2011 Jan-Feb;25(1):146-50. doi: 10.1111/j.1399-0012.2009.01198.x.
引用本文的文献
1
Clinical significance and gene prediction of a novel classification system based on tacrolimus concentration-to-dose ratio in the early post-liver transplant period.
Front Pharmacol. 2025 Jul 21;16:1614753. doi: 10.3389/fphar.2025.1614753. eCollection 2025.
2
Transplacental sirolimus: a new treatment strategy for life-threatening fetal cardiac rhabdomyomas-a case report.
Orphanet J Rare Dis. 2025 Jun 9;20(1):291. doi: 10.1186/s13023-025-03780-7.
3
Alleles of and their association with renal function in chronic kidney disease.
PeerJ. 2025 May 2;13:e19424. doi: 10.7717/peerj.19424. eCollection 2025.
4
CYP3A5 and POR gene polymorphisms as predictors of infection and graft rejection in post-liver transplant patients treated with tacrolimus - a cohort study.
Pharmacogenomics J. 2025 Feb 25;25(2):4. doi: 10.1038/s41397-025-00363-4.
5
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro.
Clin Transl Sci. 2025 Feb;18(2):e70152. doi: 10.1111/cts.70152.
6
CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms.
PeerJ. 2024 Dec 5;12:e18636. doi: 10.7717/peerj.18636. eCollection 2024.
7
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten.
Clin Pharmacol Ther. 2025 Feb;117(2):387-397. doi: 10.1002/cpt.3502. Epub 2024 Nov 25.
8
Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile.
Pharmaceuticals (Basel). 2024 Aug 7;17(8):1040. doi: 10.3390/ph17081040.
9
PharmVar GeneFocus: CYP4F2.
Clin Pharmacol Ther. 2024 Oct;116(4):963-975. doi: 10.1002/cpt.3405. Epub 2024 Aug 13.
10
Genetic Variation in , , , , and Confers Differential Susceptibility to Resistant Hypertension among South Africans.
J Pers Med. 2024 Jun 21;14(7):664. doi: 10.3390/jpm14070664.
Zotero 插件